ACNM Annual Meeting Track 

The ACNM 2022 Annual Meeting track will feature a robust program of cutting-edge educational content and oral presentations, highlighted by Richard Wahl, MD, FACNM, who will present the Mandell-Alavi Plenary Session. In addition, all meeting attendees are invited to attend ACNM Awards Ceremony and Banquet on Friday evening. During this event the ACNM will honor its 2022 ACNM Lifetime Achievement Award Winner, 2022 Gold Medal Award winner, present the ACNM Abstract Awards; and induct its 2022 Class of Fellows.


Thursday, January 27

1:30–3:30 pm ET

ACNM Oral Abstract Presentations
Organizer: Simin Dadparvar, MD, FACNM

3:45–5:45 pm ET

ACNM Oral Abstract Presentations
Organizer: Simin Dadparvar, MD, FACNM

Friday, January 28

10:00–11:30 am ET

Theranostic Nuclear Medicine is Coming-of-Age!
Sponsored by the ACNM
Organizers/Moderators:
Mark Tulchinsky, MD, FACNM, FSNMMI
Lilja B. Solnes, MD, MBA
 
Session Objectives
  • Discuss reasons for decline of I-131 therapy for hyperthyroidism.
  • Discuss main changes needed in the specialty practice and policy to ensure sustainability of Theranostic Nuclear Medicine.
  • List practical changes desirable to actualize in individual practice sites to strengthen the specialty's leadership in Theranostic space.

Presentations Include:

  • Original Disease-Radiopharmaceutical Pair: Understanding Theranostic Nuclear Medicine History to Improve the Future!
    Mark Tulchinsky, MD, FACNM, FSNMMI


10:15 am–12:15 pm ET

Mandell-Alavi Plenary Lectureship
Sponsored by the ACNM
Organizer: Gary Ulaner, MD, PhD, FACNM
Moderator: Bital Savir-Baruch, MD

Session Objectives

  • Discuss the important history of nuclear medicine
  • Examine future opportunities in Theranostics
  • Identify areas where personal contributions can enhance the field of nuclear medicine

Presentations Include:

  • Introduction of Dr. Richard Wahl
    Gary Ulaner, MD, PhD, FACNM
  • Mandell-Alavi Plenary Lectureship
    Richard Wahl, MD, FACNM
  • Panel Discussion & Q/A w/ Speakers


1:15–2:15 pm ET

Y-90 Therapy
Sponsored by the ACNM
Organizer: Bruce J. Barron, MD, MHA, FACNM
Moderator: Saima Muzahir, MBBS, MD

Session Objectives

  • Examine difference between glass and resin beads
  • Determine how to calculate dose to be delivered
  • Discuss how to deal with unexpected events

Presentations Include:

  • Y-90 Radioablation Therapy
    Bruce J. Barron, MD, MHA, FACNM
  • Y-90 Therasphere Therapy
    Saima Muzahir, MBBS, MD
  • Panel Discussion & Q/A w/ Speakers


Metastatic Thyroid Cancer

Sponsored by the ACNM
Organizer: Mark Tulchinsky, MD, FACNM, FSNMMI
Moderator: Bruce J. Barron, MD, MHA, FACNM

Session Objectives

  • Describe practical composition of Thyroid Tumor Board and Nuclear Medicine specialists' role.
  • Describe practical role of Theranostic Nuclear Medicine to the management of DTC.
  • Describe practical applications of Theranostic Nuclear Medicine principles in the selection of administered I-131 activity.

Presentations Include:

  • Theranostic Nuclear Medicine Paradigm for Optimal Management of Metastatic Differentiated Thyroid Cancer
    Mark Tulchinsky, MD, FACNM, FSNMMI


3:45–5:45 pm ET

Nuclear Medicine Theranostics in Neuroendocrine tumors: Taming the Zebras
Sponsored by the ACNM
Organizer: Ashwin Singh Parihar, MBBS, MD
Moderator: Bital Savir-Baruch, MD
 
Session Objectives

  • Discuss the imaging-guided patient selection for Peptide receptor radionuclide therapy (PRRT)
  • Describe the practical aspects of performing PRRT
  • Discuss the latest developments around PRRT
     

Presentations Include:

  • Presentation TBA
    Erik Mittra, MD, PhD 
  • Presentation TBA
    Thomas A. Hope, MD 
  • Presentation TBA
    Ashwin Singh Parihar, MBBS, MD 


Saturday, January 29

8:00–10:00 am ET

Estrogen Receptor Targeted PET with 18F-Fluoroestradiol for Patients with Breast Cancer
Sponsored by the ACNM
Organizer: Gary Ulaner, MD
Moderator: Bital Savir-Baruch, MD; Hannah M. Linden, MD

Session Objectives

  • Examine the mechanisms and principles behind 18FfluoroestradiolDescribe concept of oligometastatic in prostate cancer
  • Discuss clinical applications of 18-fluoroestradiol
  • Develop an approach for interpretation of 18Ffluoroestradiol


Presentations Include:

  • Estrogen Receptor-targeted imaging: Mechanisms and Principles
    Hannah M. Linden, MD
  • Estrogen Receptor-targeted imaging: Interpretation and Applications
    Gary Ulaner, MD, PhD, FACNM


10:00 am–12:00 pm ET

Theranostics Around the World
Sponsored by the ACNM
Organizer: Simin Dadparvar, MD, FACNM, FACR, FSNMMI
Moderator: Alan K. Klitzke, MD

Session Objectives

  • Teach applications of theranostics in treatment of liver tumors and neuroendocrine tumors
  • Discuss how to learn from our current mistakes and the future of theranostics
  • Evaluate the pros and cons for each modality of therapy


Presentations Include:

  • Intra-arterial Y-90 microsphere therapy in the Era of Theranostics: Personalized Radioembolization
    Fani Murat Bozkurt, MD
  • Theranostics in Gastroentrohepatic neuroendocrine tumors (GEP- NETS): Basic Principals and Clinical
    Applications
    Aakif Ullah Khan, MBBS, FCRS
  • Future of Theranostics
    Richard NJ Graham, MA, BM, BCh, FRCR
  • Expert Panel

 

1:30–3:30 pm ET

The Diagnosis and Management of Prostate Cancer in Nuclear Medicine
Sponsored by the ACNM
Organizer: Bital Savir-Baruch, MD
Moderator: Alan K. Klitzke, MD

Session Objectives

  • Discuss the use of FDA-approved PET tracers in prostate cancer imaging
  • Discuss Learn the concept of oligometastatic in prostate cancer
  • Examine the introduction of metastatic prostate cancer therapy


Presentations Include:

  • Prostate Cancer Imaging using FDA Approved Fluciclovine and PSMA PET Tracers
    Bital Savir-Baruch, MD
  • The Concept of Oligometastatic Disease and Prostate Cancer
    Hossein Jadvar, MD, PhD, FACNM, FSNMMI
  • Incorporation of 177Lu-PSMA-617 Into the Management of Prostate Cancer - Review of the VISION Trial
    Jeremie Calais, MD
  • Expert Panel

4:00–5:00 pm ET

Practical Considerations for Initiating an I-131 MIBG Therapy Program 
Sponsored by the ACNM
Organizer: Simin Dadparvar, MD, FACNM, FACR, FSNMMI
Moderator: Simin Dadparvar, MD, FACNM, FACR, FSNMMI

Session Objectives

  • Determine the patient criteria's eligibility for I131-MIBG therapy
  • Examine nuts and bolts of I-123 MIBG diagnostic studies
  • Evaluate the patients prior to consideration for therapy


Presentations Include:

  • Practical Considerations for Initiating an I-131 MIBG Therapy Program  
    Daniel Pryma, MD


5:00–6:00 pm ET

ACNM Annual Flipped Learning Session with a Focus on Theranostics   
Sponsored by the ACNM
Organizer: Twyla Bartel, DO, MBA, FACNM, FSNMMI
Moderator: Tracy Yarbrough, MD, PhD, MEd, FACNM

Session Objectives

  • Actively participate in a 3-step mechanism to reinforce and aid in retention of learning around theranostics.
  • Understand the imaging (functional and anatomic) and therapy available for nuclear medicine professionals currently.
  • Review specific cases related to theranostics that were presented at the entire ACNM meeting.